NCT03036488 2025-10-29
MK-3475-522
Merck Sharp & Dohme LLC
Phase 3 Completed
Clinical Trials
32 trialsNCT04174599 2025-04-20
Study to Compare the Efficacy and Safety of F-627 and GRAN®
EVIVE Biotechnology
Phase 3 Completed
NCT03197935 2023-10-26
IMpassion031
Hoffmann-La Roche
Phase 3 Completed
NCT04584112 2023-03-15
A Study of the Safety, Efficacy, and Pharmacokinetics of Tiragolumab in Combination With Atezolizumab and Chemotherapy in Participants With Triple-Negative Breast Cancer
Hoffmann-La Roche
Phase 1 Completed
NCT02190721 2021-12-10
A Study to Evaluate 5 μg/kg Tbo-filgrastim in Infants, Children and Adolescents With Solid Tumors Without Bone Marrow Involvement
Teva Branded Pharmaceutical Products R&D, Inc.
Phase 2 Completed
NCT03343145 2020-12-28
A Study to Evaluate the Efficacy, Safety and Immunogenicity of Leucostim® Versus Neupogen® in Breast Cancer Patients
Dong-A ST Co., Ltd.
Phase 3 Completed
NCT00821249 2020-10-19
A Study of ARRY-520 in Patients With Relapsed or Refractory Multiple Myeloma
Pfizer
Phase 1/2 Completed
NCT01248923 2020-09-30
A Study of ARRY-520 and Bortezomib Plus Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma
Array BioPharma
Phase 1 Completed
NCT00462358 2020-09-28
A Study of ARRY-520 in Patients With Advanced Cancer
Array BioPharma
Phase 1 Completed
NCT01416389 2019-09-18
A Study of LY2523355 in Participants With Breast Cancer
Eli Lilly and Company
Phase 2 Completed
NCT01858883 2019-07-18
Safety Study of Itacitinib (INCB039110) in Combination With Gemcitabine and Nab-Paclitaxel in Subjects With Advanced Solid Tumors
Incyte Corporation
Phase 1/2 Completed
NCT01031368 2019-03-01
Clofarabine, Cytarabine, and Filgrastim Followed by Infusion of Non-HLA Matched Ex Vivo Expanded Cord Blood Progenitors in Treating Patients With Acute Myeloid Leukemia
Nohla Therapeutics, Inc.
Phase 1 Completed
NCT02282215 2018-09-27
Safety and Efficacy of Human Myeloid Progenitor Cells (CLT-008) During Chemotherapy for Acute Myeloid Leukemia
Cellerant Therapeutics
Phase 2 Completed
NCT02521441 2018-02-23
A Phase II, Dose-finding Study of F-627 in Patients With Breast Cancer Receiving Myelotoxic Chemotherapy.
EVIVE Biotechnology
Phase 2 Completed
NCT01569087 2016-12-05
Dose-finding Study of Empegfilgrastim for Neutropenia Prophylaxis in Patients With Breast Cancer
Biocad
Phase 2 Completed
NCT02104830 2016-10-24
Study of the Efficacy and Safety of Empegfilgrastim for Neutropenia Prophylaxis in Breast Cancer Patients
Biocad
Phase 3 Completed
NCT01297543 2016-07-01
Safety Study of Human Myeloid Progenitor Cells (CLT-008) After Chemotherapy for Leukemia
Cellerant Therapeutics
Phase 1/2 Completed
NCT02805153 2016-06-20
PEG-rhG-CSF in Patients With Breast Cancer Receiving Chemotherapy
CSPC Baike (Shandong) Biopharmaceutical Co., Ltd.
Phase 4 Completed
NCT02221492 2016-03-30
Plerixafor Plus Granulocyte Colony-Stimulating Factor For Mobilization And Collection Of Peripheral Hematopoietic Stem Cells In Japanese Participants With Non-Hodgkin Lymphoma
Sanofi
Phase 2 Completed
NCT02221479 2015-08-04
Plerixafor Plus Granulocyte Colony-stimulating Factor (G-CSF) For Mobilization And Collection Of Peripheral Hematopoietic Stem Cells In Japanese Participants With Multiple Myeloma
Sanofi
Phase 2 Completed
NCT01519700 2015-05-06
PIONEER
Sandoz
Phase 3 Completed
NCT01767714 2014-12-09
Evaluation of Plerixafor Plus G-CSF to Mobilize and Collect 5×10^6CD34+ Cells/kg in Non-Hodgkin's Lymphoma (NHL) Patients for Autologous Transplantation
Sanofi
Phase 3 Completed
NCT01164475 2014-02-25
Evaluation of Approved Weight-Based Dose Compared to Fixed Dose of Plerixafor in Patients With Non-Hodgkin's Lymphoma (NHL) Weighing Less Than 70 Kilograms
Sanofi
Phase 4 Completed
NCT01079676 2012-10-16
A Non-inferiority Study Comparing Two Filgrastim Preparations in Breast Cancer
Eurofarma Laboratorios S.A.
Phase 3 Completed
NCT00004212 2012-05-16
DX-8951f in Treating Children With Advanced Solid Tumors or Lymphomas
Daiichi Sankyo
Phase 1 Completed
NCT00616213 2011-06-01
PR104 and G-CSF in Treating Patients With Solid Tumors
Proacta, Incorporated
Phase 1 Completed
NCT00035620 2010-02-26
Pegfilgrastim as Support to Pediatric Sarcoma Patients Receiving Chemotherapy
Amgen
Phase 2 Completed
NCT00776165 2010-02-03
Safety and Efficacy Trial of Recombinant Human Granulocyte Colony Stimulating Factor (GCSF)
Shantha Biotechnics Limited
Phase 3 Completed
NCT00117897 2009-07-20
Treatment for Subjects With Non-Hodgkin's Lymphoma
Amgen
Phase 2 Completed
NCT00114764 2008-10-31
Trial Comparing Pegfilgrastim With Filgrastim as an Adjunct to Chemotherapy for Acute Myeloid Leukaemia (AML)
Amgen
Phase 2 Completed
NCT00117455 2008-05-16
A Study of Peripheral Blood Progenitor Cell (PBPC) Mobilisation by Chemotherapy With Pegfilgrastim or Filgrastim in Subjects With Non-Hodgkin's Lymphoma
Amgen
Phase 2 Completed
NCT00066092 2008-02-28
Pegfilgrastim PBPC Mobilization Study
Amgen
Phase 2 Completed